Literature DB >> 29254785

Impact of DNA repair, folate and glutathione gene polymorphisms on risk of non small cell lung cancer.

Cristina Pérez-Ramírez1, Marisa Cañadas-Garre2, Ahmed Alnatsha3, Eduardo Villar4, Juan Ramón Delgado5, Miguel Ángel Calleja-Hernández6, María José Faus-Dáder7.   

Abstract

Lung cancer, particularly non-small cell lung cancer (NSCLC) subtype, is the leading cause of cancer-related death related worldwide. Numerous gene polymorphisms in DNA repair, folate and glutathione pathways have been associated with susceptibility of NSCLC. We conducted this study to evaluate the effects of ERCC1, ERCC2, ERCC5, XRCC1, XRCC3, MTHFR, MTR, MTHFD1, SLC19A1 and GSTP1 gene polymorphisms on risk of NSCLC. No association between these gene polymorphisms and susceptibility of NSCLC were found in our patients, suggesting that genetic variations in genes involved in DNA repair, folate and glutathione metabolism pathways may not influence the risk of NSCLC.
Copyright © 2017 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  DNA repair pathway; Folate metabolism pathway; Glutathione metabolism pathway; Non-small cell lung cancer; Polymorphisms; Risk

Mesh:

Substances:

Year:  2017        PMID: 29254785     DOI: 10.1016/j.prp.2017.11.015

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  3 in total

1.  Genetic polymorphism of drug metabolism enzymes (GSTM1, GSTT1 and GSTP1) in the healthy Malian population.

Authors:  Yaya Kassogue; Brehima Diakite; Oumar Kassogue; Issa Konate; Kadidiatou Tamboura; Zoumana Diarra; Hind Dehbi; Sellama Nadifi; Cheick Bougadari Traore; Sounkalo Dao; Seydou Doumbia; Guimogo Dolo
Journal:  Mol Biol Rep       Date:  2019-10-24       Impact factor: 2.316

2.  Rs3212986 polymorphism, a possible biomarker to predict smoking-related lung cancer, alters DNA repair capacity via regulating ERCC1 expression.

Authors:  Tao Yu; Ping Xue; Su Cui; Liang Zhang; Guopei Zhang; Mingyang Xiao; Xiao Zheng; Qianye Zhang; Yuan Cai; Cuihong Jin; Jinghua Yang; Shengwen Wu; Xiaobo Lu
Journal:  Cancer Med       Date:  2018-11-19       Impact factor: 4.452

3.  Discovery of Novel Biomarkers of Therapeutic Responses in Han Chinese Pemetrexed-Based Treated Advanced NSCLC Patients.

Authors:  Xiaoqing Zhang; Di Zhang; Lihua Huang; Guorong Li; Luan Chen; Jingsong Ma; Mo Li; Muyun Wei; Wei Zhou; Chenxi Zhou; Jinhang Zhu; Zhanhui Wang; Shengying Qin
Journal:  Front Pharmacol       Date:  2019-08-23       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.